Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > All take a deep breath

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jul 05, 2022 11:20pm

169 Views

Post# 34804031

RE:All take a deep breath

I have a question.

I'm not holding my breath for a large increase in revenue but is there a smaller amount of growth say in Egrifta that might change some of the metrics around a financing or re-financing of the debt? What sort of minimum increase in revenue could make them more attractive to lend to?

palinc2000 wrote: and relax!!!
THTX 's fair market value is not reflected in the SP...
The stock is not traded ....no sellers and no buyers

Almost 100 million shares outstanding and a few thousand shares change hands

Fixating only at TH 1902 is only one component of THTX